Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease.

Journal: The lancet. Gastroenterology & hepatology
Published Date: May 14, 2024

Abstract

Integrating artificial intelligence into inflammatory bowel disease (IBD) has the potential to revolutionise clinical practice and research. Artificial intelligence harnesses advanced algorithms to deliver accurate assessments of IBD endoscopy and histology, offering precise evaluations of disease activity, standardised scoring, and outcome prediction. Furthermore, artificial intelligence offers the potential for a holistic endo-histo-omics approach by interlacing and harmonising endoscopy, histology, and omics data towards precision medicine. The emerging applications of artificial intelligence could pave the way for personalised medicine in IBD, offering patient stratification for the most beneficial therapy with minimal risk. Although artificial intelligence holds promise, challenges remain, including data quality, standardisation, reproducibility, scarcity of randomised controlled trials, clinical implementation, ethical concerns, legal liability, and regulatory issues. The development of standardised guidelines and interdisciplinary collaboration, including policy makers and regulatory agencies, is crucial for addressing these challenges and advancing artificial intelligence in IBD clinical practice and trials.

Authors

  • Marietta Iacucci
    National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK.
  • Giovanni Santacroce
    APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, T12 YT20, Ireland.
  • Irene Zammarchi
    APC Microbiome Ireland, College of Medicine and Health, University College of Cork, Cork, Ireland.
  • Yasuharu Maeda
    Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.
  • Rocío Del Amor
    Instituto Universitario de Investigación en Tecnología Centrada en el Ser Humano (HUMAN-Tech), Universitat Politècnica de València, 46022, Spain.
  • Pablo Meseguer
    Instituto de Investigación e Innovación en Bioingeniería, HUMAN-tech, Universitat Politècnica de València, València, Spain; Valencian Graduate School and Research Network of Artificial Intelligence, Valencia, Spain.
  • Bisi Bode Kolawole
    School of Engineering, London South Bank University, London, UK.
  • Ujwala Chaudhari
    School of Engineering, London South Bank University, London, UK.
  • Antonio Di Sabatino
    Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy; First Department of Internal Medicine, San Matteo Hospital Foundation, Pavia, Italy.
  • Silvio Danese
    Inflammatory Bowel Disease Center and Department of Biomedical Sciences, Humanitas Clinical and Research Center, Humanitas University, Milan, Italy.
  • Yuichi Mori
    Clinical Effectiveness Research Group, Institute of Health and Society, University of Oslo, and Department of Transplantation Medicine Oslo University Hospital, Oslo, Norway; Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan. Electronic address: ibusiginjp@gmail.com.
  • Enrico Grisan
    Department of Information Engineering, University of Padova, Padova, Italy.
  • Valery Naranjo
    Instituto de Investigación e Innovación en Bioingeniería, I3B, Universitat Politècnica de València, Camino de Vera s/n, 46022, Valencia, Spain.
  • Subrata Ghosh
    Professor of Medicine and Gastroenterology, Director, Institute of Translational Medicine, University of Birmingham, Edgbaston, Birmingham, B15 2TH, UK.

Keywords

External Resources

Popular Topics
Recent Journals